Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) have been given a consensus rating of “Moderate Buy” by the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $33.3333.

Several analysts recently weighed in on CRVS shares. Weiss Ratings raised shares of Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. LADENBURG THALM/SH SH upgraded shares of Corvus Pharmaceuticals to a “strong-buy” rating in a report on Thursday, July 30th. Finally, Wall Street Zen downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th.

Corvus Pharmaceuticals Price Performance

Shares of NASDAQ CRVS opened at $14.89 on Friday. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -24.41 and a beta of 0.87. The stock’s 50-day moving average is $13.72 and its two-hundred day moving average is $15.14. Corvus Pharmaceuticals has a 1-year low of $4.92 and a 1-year high of $26.95.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.03). Equities research analysts anticipate that Corvus Pharmaceuticals will post -0.79 earnings per share for the current fiscal year.

Insider Activity

In other news, Director David Scott Moore acquired 21,700 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was acquired at an average cost of $11.53 per share, with a total value of $250,201.00. Following the transaction, the director owned 21,700 shares in the company, valued at approximately $250,201. This trade represents a ? increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 19.70% of the company’s stock.

Institutional Trading of Corvus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of CRVS. Quarry LP purchased a new stake in Corvus Pharmaceuticals during the 3rd quarter worth about $27,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Corvus Pharmaceuticals by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,629 shares of the company’s stock worth $28,000 after acquiring an additional 748 shares in the last quarter. Global Retirement Partners LLC purchased a new position in shares of Corvus Pharmaceuticals in the 2nd quarter valued at about $30,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Corvus Pharmaceuticals in the 2nd quarter valued at about $48,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Corvus Pharmaceuticals during the 3rd quarter worth about $49,000. 46.64% of the stock is currently owned by institutional investors and hedge funds.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.